Response to letter entitled: Re: Pathologic Complete Responses, Long-term Outcomes, and Recurrence Patterns in HER2-low vs. HER2-zero Breast Cancer after Neoadjuvant Chemotherapy
- PMID: 36529603
- DOI: 10.1016/j.ejca.2022.11.019
Response to letter entitled: Re: Pathologic Complete Responses, Long-term Outcomes, and Recurrence Patterns in HER2-low vs. HER2-zero Breast Cancer after Neoadjuvant Chemotherapy
Conflict of interest statement
Conflict of interest statement The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: SB Kim received research funding from Novartis, Sanofi-Aventis, and DongKook Pharm Co. He has been a consultant on advisory boards for Novartis, AstraZeneca, Lilly, Dae Hwa Pharmaceutical Co. Ltd, ISU Abxis, OBI Pharma, Beigene, and Daiichi-Sankyo. He owns stocks of Genopeaks and NeogeneTC. S Kang has no conflict of interest.
Comment on
-
Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy.Eur J Cancer. 2022 Nov;176:30-40. doi: 10.1016/j.ejca.2022.08.031. Epub 2022 Sep 29. Eur J Cancer. 2022. PMID: 36183652
-
Re: Pathologic complete responses, long-term outcomes, and recurrence patterns in HER2-low vs. HER2-zero breast cancer after neoadjuvant chemotherapy: Several issues about HER2 expression and neoadjuvant chemotherapy in breast cancer.Eur J Cancer. 2023 Feb;180:184-185. doi: 10.1016/j.ejca.2022.11.018. Epub 2022 Dec 27. Eur J Cancer. 2023. PMID: 36581473 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous